The course focuses on precision medicine, discussing the current main application methods, products and markets of PCR genetic testing and next-generation genetic sequencing in Taiwan. A companion diagnostic refers to medical testing assays that can ensure effectiveness and safety of drugs or bio-related products for patient treatment. It is usually performed by in vitro diagnostic tests (IVD) or laboratory development tests (LDTs). With the rapid development of precision medicine, many biomedical scientists are committed to developing novel non-invasive methods termed liquid biopsy which could replace traditional tumor tissue sectioning. Liquid biopsy refers to the assays that are able to obtain cancer information by taking liquid samples such as blood or urine from a patient. Using the molecular diagnostic assays (companion diagnostic and liquid biopsy), doctors could choose the best medications and modality for the patient. Hence, the patient has a better survival outcome than before. With the continuous innovations and improvements of molecular diagnostic technology, cancer treatment certainly is going be improved, which will help patients receive the most accurate and effective diagnosis and prescriptions. This course enables students to understand the principles, have fingers on the pulse of the industry as well as develop skills.